Modular Nanotechnologies for Cancer Drug Screening

描述：(申请人提供) 我们建议进一步开发、多元化和应用新的纳米技术， 在第一阶段中演示了这些技术将首次实现 高效、高通量的药物筛选将识别新的化合物 阻止活细胞表面的配体-受体相互作用。我们会 靶向特异性细胞表面受体，已被牵连到 肿瘤的发生、转移和血管生成。第二种体外纳米材料 技术将扩展到筛选以蛋白质为基础的合成模拟物 药物，如抗体和天然产物。这些化验结果将是 专门为鉴定已知血管生成的合成模拟物而开发 抑制剂，大规模生产成本可能令人望而却步。大的， 作为该项目的一部分，将筛选化学上不同的药库。 建议的商业应用： 第一阶段展示的技术具有巨大的商业潜力。一 技术使高通量筛选一类涉及的靶受体成为可能 在癌症中，迄今为止很难用相关的方法进行检测。另一个 技术提供了一种直接的方法来识别合成的药物模拟物，这些药物也 大量生产的成本很高。这些技术是模块化的，因此很容易适应 以方便筛选各种目标，而无需进一步修改 平台技术。无论是技术还是任何已确定的药物线索都将是 是制药公司极为感兴趣的。

DESCRIPTION: (provided by applicant) We propose to further develop, multiplex, and apply novel nanotechnologies, demonstrated in Phase I. These technologies will, for the first time, enable effective, high throughput drug screening that will identify novel compounds that block ligand-receptor interactions on the surface of live cells. We will target specific cell surface receptors that have been implicated in tumorigenesis, metastasis and angiogenesis. A second in vitro nano-based technology will be extended to screen for synthetic mimics of protein-based drugs, such as antibodies and natural products. These assays will be specifically developed to identify synthetic mimics of known angiogenesis inhibitors, for which large-scale production costs may be prohibitive. Large, chemically diverse drug libraries will be screened as a part of this project. PROPOSED COMMERCIAL APPLICATION: The technologies demonstrated in Phase I have significant commercial potential. One technology enables high throughput screening for a class of target receptors implicated in cancer that have heretofore been difficult to assay in a relevant way. The other technology offers a direct approach to identifying synthetic mimics of drugs that are too costly to produce in mass quantities. The technologies are modular and thus easily adapted to facilitate screening of a wide variety of targets without further modification to the platform technology. Both the technologies as well as any drug leads identified would be of extreme interest to pharmaceutical companies.